Nura Bio Debuts With $73M and Plan to Develop “Neuroprotective” Drugs
Summary
Nura Bio Debuts With $73M and Plan to Develop “Neuroprotective” Drugs Damage to axons, the slender tendrils through which nerve cells communicate, is an early indication of several neurological diseases. Nura Bio, which formed around new research into a mechanism underlying axonal degeneration, made its public debut Wednesday with a $73 million financing round and a chief executive who has experience shepherding multiple drug development programs from discovery to commercialization. That discovery was made in the lab of Marc Freeman, who directs the Vollum Institute at Oregon Health & Science University. The pair, with the Column Group, which led Nura’s Series A funding with participation from Samsara BioCapital and Euclidean Capital, started the company in 2018. Since inception, Nura has built a pipeline of preclinical drugs designed to target axonal degeneration and neuroinflammation, but the company hasn’t yet determined which indications to pursue within the broad range of conditions it believes its investigational therapeutics can address, Seth says.
Classifications
AskAI Classifications
LabelsLinked Companies
